CHO Cell Line

Thermo Fisher Scientific Launches New Biologics Development Platform to Accelerate Innovation

By BiotechReality Business Intelligence Desk
4 April 2026

Thermo Fisher Scientific has unveiled the Gibco CHOvantage GS, a next-generation biologics development platform designed to accelerate timelines to the clinic while ensuring regulatory compliance and scalability.

News Research

A long-standing challenge with CHO cell line is solved by a new understanding of lactic acid metabolism in cells

By Editor's Desk
15 January 2025

Chinese hamster ovary (CHO) cells are frequently used to produce protein-based medications for the treatment of cancer, autoimmune disorders, and other conditions. A multinational team [Read More…]

Tag: CHO Cell Line

Thermo Fisher Scientific Launches New Biologics Development Platform to Accelerate Innovation

A long-standing challenge with CHO cell line is solved by a new understanding of lactic acid metabolism in cells

Areas Covered

Discover More

LIPFENDRA FDA Approval: Merck’s Enlicitide Becomes First Oral PCSK9 Inhibitor to Lower LDL-C

GSK Nuvalent Acquisition: GSK Completes $10.6 Billion Nuvalent Acquisition, Expanding Lung Cancer Pipeline

Johnson & Johnson Q2 2026 Analysis: Company Reports $25.3 Billion in Sales, Raises Full-Year Outlook

Merck’s Erbitux BRAF V600E mCRC Regimen Gets EU Approval for First-Line Treatment

AstraZeneca Zegfrovy Deal: AstraZeneca Licenses Dizal’s Oral EGFR Inhibitor for Lung Cancer in Up to $1.5 Billion Agreement

Charles River NGS Services Power Arovella Therapeutics’ ALA-101 Cell Therapy Manufacturing